Amanda L. Blackford

Johns Hopkins University

Full Professor(heuristic)

Pancreatic and Hepatic Oncology Research · Oncology

h-index61

i10-index168

Publications467

Citations13,179

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 53

Federal housing assistance, cancer care, and overall survival among older adults with prostate cancer
JNCI Journal of the National Cancer Institute · 2026-04-15
Abstract 3675: Identifying determinants of molecular testing for advanced non-small cell lung cancer in the rural United States
Cancer Research · 2026-04-03
1540 Well-Differentiated Neuroendocrine Tumors Metastatic to the Pancreas Can Mimic Primary Well-Differentiated Pancreatic Neuroendocrine Tumors: Clinical and Pathologic Features in a Multi-Institutional and International Study
Laboratory Investigation · 2026-03-01
1506 Pathologic Characteristics and Prognostic Features of Well-Differentiated Pancreatic Neuroendocrine Tumors in MEN1 Syndrome: a case-control study in a series of 39 MEN1 patients and 778 non-MEN1 patients with 7752 person-year follow-up
Laboratory Investigation · 2026-03-01
1530 Artificial Intelligence Based-Prediction of Recurrence of Surgically Resected Pancreatic Neuroendocrine Tumors in a Multi-Institutional Cohort Reveals Histological Patterns Associated with Risk
Laboratory Investigation · 2026-03-01
1505 Glucagon-Like Peptide-1 Receptor (GLP-1R) Expression in Well-Differentiated Pancreatic Neuroendocrine Tumors (PanNETs) and its Potential Role in Predicting the Patient Outcomes
Laboratory Investigation · 2026-03-01
Reply
Gastro Hep Advances · 2026-01-01
Supplementary Table S6 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S1 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Figure S3 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S5 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S3 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Figure S1 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Figure S4 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Data from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S2 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Table S4 from Personalizing CA125 Levels Using Tumor Marker Variants: A Case–Control Analysis of Diagnostic Performance for Pancreatic Cancer
2025-12-01
Supplementary Data 1 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
2025-11-25
Supplementary Data Tables S1-S5 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
2025-11-25
Supplementary Data 2 from Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
2025-11-25

Open author page on OpenAlex →